SynthesisAmerican journal of Alzheimer's disease and other dementias2015
Role of traditional nonsteroidal anti-inflammatory drugs in Alzheimer's disease: a meta-analysis of randomized clinical trials.
Synthesis in American journal of Alzheimer's disease and other dementias, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Feasibility of identifying factors related to Alzheimer's disease and related dementia in real-world data.JAMIA open · 2026Review
- Immunotherapies for risk reduction in age-associated neurodegenerative diseases: impact of sex and treatment duration.medRxiv : the preprint server for health sciences · 2026Article
- Anti-inflammatory and immunomodulatory therapies are associated with reduced risk of age-associated neurodegenerative diseases: impact of sex and treatment duration.Frontiers in aging neuroscience · 2026Article
- Long-Term Exposure to Non-Steroidal Anti-Inflammatory Medication in Relation to Dementia Risk.Journal of the American Geriatrics Society · 2025Article
- The anti-inflammatory drug Montelukast ameliorates cognitive deficits by rescuing the inflammatory levels in young AD animal models.Scientific reports · 2025Article
- Advances in Therapeutics to Alleviate Cognitive Decline and Neuropsychiatric Symptoms of Alzheimer's Disease.International journal of molecular sciences · 2024Review
- Repercussion of Primary Nucleation Pathway: Dementia and Cognitive Impairment.Current aging science · 2024Review
- Modulation of LPS-Induced Neurodegeneration by Intestinal Helminth Infection in Ageing Mice.International journal of molecular sciences · 2023Article
- Article
- Inhibition of the CEBPβ-NFκB interaction by nanocarrier-packaged Carnosic acid ameliorates glia-mediated neuroinflammation and improves cognitive function in an Alzheimer's disease model.Cell death & disease · 2022Article
- Macrocyclic Immunoproteasome Inhibitors as a Potential Therapy for Alzheimer's Disease.Journal of medicinal chemistry · 2021Article
- A dual inhibitor of the proteasome catalytic subunits LMP2 and Y attenuates disease progression in mouse models of Alzheimer's disease.Scientific reports · 2019Article
- New treatment modalities in Alzheimer's disease.World journal of clinical cases · 2019Review
- Recommendations for Anti-inflammatory Treatments in Alzheimer's Disease: A Comprehensive Review of the Literature.Cureus · 2019Review
- Precision pharmacology for Alzheimer's disease.Pharmacological research · 2018Review
- Current understanding of Alzheimer's disease diagnosis and treatment.F1000Research · 2018Review
- Androgen alleviates neurotoxicity of β-amyloid peptide (Aβ) by promoting microglial clearance of Aβ and inhibiting microglial inflammatory response to Aβ.CNS neuroscience & therapeutics · 2017Article
- Reduced cerebrospinal fluid concentration of interleukin-12/23 subunit p40 in patients with cognitive impairment.PloS one · 2017Article
- The dual roles of cytokines in Alzheimer's disease: update on interleukins, TNF-α, TGF-β and IFN-γ.Translational neurodegeneration · 2016Review
- Insulin resistance in Alzheimer's disease.Neurobiology of disease · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of nonsteroidal anti-inflammatory drugs (NSAIDs) in prevention of Alzheimer's disease (AD) has been evaluated in many studies. We performed a meta-analysis to summarize the existing evidence on the relation between use of classical NSAIDs and AD. Randomized controlled trials (RCTs) evaluating the role of classical NSAIDs in AD was searched using different search engines. The RCTs in patients who had the degree of AD measured on Mini-Mental State Examination (MMSE) or AD Assessment Scale-Cognitive subscale (ADAS-cog) were included in the study. The RCTs and data (AD scores) were independently assessed by 2 reviewers, and data were included in meta-analysis only after a common consensus was reached. The pooled results from the ADAS-cog and MMSE scores failed to show any difference between the treatment and the placebo groups as opposed to findings from some observational studies. However, in view of heterogeneity of results, there is a need to conduct more RCTs to arrive at confirmatory findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.